CTLA4 and head and neck squamous cell carcinoma: On the other hand, the CONDOR study evaluated durvalumab along with an anti-CTLA-4 mAb tremelimumab, or durvalumab and tremelimumab combination in patients with PD-L1-low/negative R/M HNSCC (TC < 25%).